Transfer factor in chronic mucocutaneous candidiasis.
Fifteen patients suffering from chronic mucocutaneous candidiasis were treated with an in vitro produced TF specific for Candida albicans antigens and/or with TF extracted from pooled buffy coats of blood donors. CMI of the patients was assessed using the LMT and the LST in presence of candidine. The aim of the study was the clinical evaluation of TF treatment and the incidence of positive tests before, during, and after therapy. Immunological data were matched using the Chi square test. 87 LMT were performed for each antigen dose and at the dilution of 1/50, 58.9% (33/56) tests were positive during non-treatment or non-specific TF treatment. On the contrary 83.9% (26/31) were positive during specific TF treatment (P < 0.05). In the LST, a significant decrease of thymidine uptake in the control cultures in presence of autologous or AB serum was observed when patients were matched according to non-treatment, and both non specific (P < 0.05) and specific TF treatment (P < 0.01). Only during specific TF treatment was a significant increase of reactivity against the Candida antigen at the highest concentration noticed, when compared with the period of non specific treatment (P < 0.01). Clinical observations were encouraging: all but one patient experienced significant improvement during treatment with specific TF. These data confirm that orally administered specific TF, extracted from induced lymphoblastoid cell-lines, increases the incidence of reactivity against Candida antigens in the LMT. LST reactivity appeared not significantly increased with respect to the periods of non treatment, but was significantly increased when it was compared to the non-specific TF treatment periods. At the same time, a clinical improvement was noticed.
Masi
M
M
Department of Pediatrics, University of Bologna, Italy.
De Vinci
C
C
Baricordi
O R
OR
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000935:Antifungal Agents / Q000276:immunology / Q000627:therapeutic use*; D000946:Antigens, Fungal / Q000276:immunology; D002176:Candida albicans / Q000276:immunology; D002178:Candidiasis, Chronic Mucocutaneous / Q000276:immunology / Q000628:therapy*; D002464:Cell Migration Inhibition; D002648:Child; D000939:Epitopes; D005260:Female; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects / Q000276:immunology; D008213:Lymphocyte Activation / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D013268:Stimulation, Chemical; D014165:Transfer Factor / Q000276:immunology / Q000627:therapeutic use*
D000276:Adjuvants, Immunologic; D000935:Antifungal Agents; D000946:Antigens, Fungal; D000939:Epitopes; D014165:Transfer Factor